KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Operating Leases: 2020-2024

Historic Operating Leases for Aquestive Therapeutics (AQST) over the last 5 years, with Dec 2024 value amounting to $5.0 million.

  • Aquestive Therapeutics' Operating Leases fell 8.62% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 8.62%. This contributed to the annual value of $5.0 million for FY2024, which is 7.98% down from last year.
  • Aquestive Therapeutics' Operating Leases amounted to $5.0 million in FY2024, which was down 7.98% from $5.4 million recorded in FY2023.
  • Aquestive Therapeutics' Operating Leases' 5-year high stood at $5.4 million during FY2023, with a 5-year trough of $1.9 million in FY2021.
  • In the last 3 years, Aquestive Therapeutics' Operating Leases had a median value of $5.1 million in 2022 and averaged $5.2 million.
  • In the last 5 years, Aquestive Therapeutics' Operating Leases slumped by 31.62% in 2021 and then spiked by 161.31% in 2022.
  • Over the past 5 years, Aquestive Therapeutics' Operating Leases (Yearly) stood at $2.8 million in 2020, then tumbled by 31.62% to $1.9 million in 2021, then soared by 161.31% to $5.1 million in 2022, then climbed by 6.18% to $5.4 million in 2023, then fell by 7.98% to $5.0 million in 2024.